Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan

References

• World Health OrganizationA global brief on hypertension. Silent killer, global public health crisisGeneva, SwitzerlandWorld Health Organization2013 Available from: http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/Accessed August 20, 2013
   Google Scholar
• WhitworthJAWorld Health Organization, International Society of Hypertension Writing Group2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertensionJ Hypertens2003211983199214597836
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSBanegasJRHypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United StatesJAMA20032892363236912746359
   PubMed Web of Science ®Google Scholar
• BrunnerHRThe new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerationsAm J Hypertens19971012 Pt 2311S317S9438775
   PubMed Web of Science ®Google Scholar
• BurnierMAngiotensin II type 1 receptor blockersCirc J2001103904912
   Google Scholar
• WaeberBA review of the clinical experience with the angiotensin II Receptor antagonist irbesartanCardiovasc Drug Rev200018103126
   Google Scholar
• TikkanenIJensenHComparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertensionJ Hypertens199513134313518984133
   PubMed Web of Science ®Google Scholar
• RuffDGazdickLPBermanRGoldbergAISweetCSComparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertensionJ Hypertens1996142632708728306
   PubMed Web of Science ®Google Scholar
• HolwerdaNJFogariRAngeliPValsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalaprilJ Hypertens199614114711518986917
   PubMed Web of Science ®Google Scholar
• GradmanAHArcuriKEGoldbergAIA randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertensionHypertension199525134513507768585
   PubMed Web of Science ®Google Scholar
• GoldbergAIDunlayMCSweetCSSafety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertensionAm J Cardiol1995757937957717281
   PubMed Web of Science ®Google Scholar
• WeberMAByynyRLPrattJHBlood pressure effects of the angiotensin II receptor blocker, losartanArch Intern Med19951554054117848024
   PubMed Web of Science ®Google Scholar
• WeirMRElkinsMLissCVrecenakAJBarrEEdelmanJMEfficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertensionClin Ther1996184114288829017
   PubMed Web of Science ®Google Scholar
• OparilSDykeSHarrisFThe efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertensionClin Ther1996187978108930424
   PubMed Web of Science ®Google Scholar
• NeutelJWeberMPoolJValsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hoursClin Ther1997194474589220209
   PubMed Web of Science ®Google Scholar
• FogariRAmbrosoliSCorradiL24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators’ GroupJ Hypertens199715151115189431859
   PubMed Web of Science ®Google Scholar
• PoolJLGuthrieRMLittlejohnTW3rdDose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertensionAm J Hypertens1998114624709607385
   PubMed Web of Science ®Google Scholar
• LarochellePFlackJMMarburyTCSareliPKriegerEMReevesRAEffects and tolerability of irbesartan versus enalapril in patients with severe hypertensionAm J Cardiol199780161316159416950
   PubMed Web of Science ®Google Scholar
• MimranARuilopeLKerwinLA randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertensionJ Hum Hypertens1998122032089579771
   PubMed Web of Science ®Google Scholar
• StumpeKOHaworthDHoglundCComparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertensionBlood Press1998731379551875
   PubMedGoogle Scholar
• LoMWGoldbergMRMcCreaJBLuHFurtekCIBjornssonTDPharmacokinetics of losartan, an antagonist II receptor antagonist and its active metabolite EXP3174 in humansClin Pharmacol Ther1995586416498529329
   PubMed Web of Science ®Google Scholar
• VachharajaniNNShyuWCChandoTJEverettDWGreeneDSBarbhaiyaRHOral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteersJ Clin Pharmacol1998387022079725545
   PubMed Web of Science ®Google Scholar
• WaldmeierFFleschGMüllerPPharmacokinetics, disposition and biotransformation of [14C] radiolabelled valsartan in health male volunteers after a single oral doseXenobiotica19972759719041679
   PubMed Web of Science ®Google Scholar
• CriscioneLBradleyWABühlmayerPValsartan: preclinical profile of an antihypertensive angiotensin II antagonistCardiovasc Drug Rev199513230250
   Web of Science ®Google Scholar
• MarinoMRLangenbacherKFordNFUdermanHDPharmacokinetics and pharmacodynamics of irbesartan in healthy subjectsJ Clin Pharmacol1998382462559549663
   PubMed Web of Science ®Google Scholar
• ChandoTJEverettDWKahleADBiotransformation of irbesartan in manDrug Metab Dispos1998264084179571222
   PubMed Web of Science ®Google Scholar
• PowellJRReevesRAMarinoMRA review of the new angiotensin II-receptor antagonist irbesartanCardiovasc Drug Rev199816169194
   Google Scholar
• BourriéMMeunierVBergerYFabreGRole of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomesDrug Metab Dispos1999272882969929518
   PubMed Web of Science ®Google Scholar
• MarinoMVachharajaniNPharmacokinetics of irbesartan are not altered in special populationsJ Cardiovasc Pharmacol20024011212212072584
   PubMed Web of Science ®Google Scholar
• VachharajaniNNShyuWCSmithRAGreeneDSThe effects of age and gender on the pharmacokinetics of irbesartanBr J Clin Pharmacol1998466116139862252
   PubMed Web of Science ®Google Scholar
• SakarcanATenneyFWilsonJTThe pharmacokinetics of irbesartan in hypertensive children and adolescentsJ Clin Pharmacol20014174274911452706
   PubMed Web of Science ®Google Scholar
• SicaDAMarinoMRHammettJLFerreiraIGehrTWFordNFThe pharmacokinetics of irbesartan in renal failure and maintenance hemodialysisClin Pharmacol Ther199766106189433389
   PubMedGoogle Scholar
• MarinoMLangenbacherKRaymondRHPharmacokinetics and pharmacodynamics of irbesartan in patient with hepatic cirrhosisJ Clin Pharmacol199843473569590462
   PubMedGoogle Scholar
• KostisJBVachharajaniNHadjilambrisOWThe pharmacokinetics and pharmacodynamics of irbesartan in heart failureJ Clin Pharmacol2001993594211549097
   PubMedGoogle Scholar
• MangoldBGielsdorfWMarinoMRIrbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarinEur J Clin Pharmacol19995559359810541778
   PubMed Web of Science ®Google Scholar
• MarinoMRVachharajaniNNHadjilambrisOWIrbesartan does not affect the pharmacokinetics of simvastatin in healthy subjectsJ Clin Pharmacol20004087587910934672
   PubMed Web of Science ®Google Scholar
• MarinoMRLangenbacherKMFordNFEffect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin II blocker irbesartanClin Drug Investig199714383391
   Web of Science ®Google Scholar
• MarinoMHammettJLFerreiraILack of effect of nifedipine on the pharmacokinetics of irbesartan in healthy male subjectsJ Clin Pharmacol199737872
   Google Scholar
• MazzolaiLMaillardMRossatJNussbergerJBrunnerHRBurnierMAngiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonistsHypertension19993385085510082498
   PubMed Web of Science ®Google Scholar
• RibsteinJPicardAArmagnacCFull antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normotensive subjectsJ Hypertens199715S117
   PubMedGoogle Scholar
• RibsteinJSissmannJPicardABouroudianMMimranAEffects of the angiotensin-II antagonist SR47436 (BMS 186295) on the pressor response to exogenous angiotensin-II and the renin-angiotensin system in sodium replete normal subjectsJ Hypertens199412131
   Google Scholar
• MarinoMRLangenbacherKMFordNFPharmacokinetics and pharmacodynamics of irbesartan in patients with mild to moderate hypertensionJ Cardiovasc Pharmacol Ther19994677510684525
   PubMedGoogle Scholar
• Pechère-BertschiANussbergerJDecosterdLRenal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patientsJ Hypertens1998163853939557932
   PubMed Web of Science ®Google Scholar
• SchmittFMartinezFBrilletGAcute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjectsJ Cardiovasc Pharmacol1998313143219475275
   PubMed Web of Science ®Google Scholar
• Kassler-TaubKLittlejohnTElliottWRuddyTAdlerEComparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertensionAm J Hypertens1998114454539607383
   PubMed Web of Science ®Google Scholar
• Morales-OlivasFJArísteguiIEstañLThe KARTAN study: a postmarketing assessment of Irbesartan in patients with hypertensionClin Ther20042623234415038946
   PubMed Web of Science ®Google Scholar
• ChiouKRChenCHDingPYRandomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertensionZhonghua Yi Xue Za Zhi (Taipei)20006336837610862446
   PubMedGoogle Scholar
• CocaACalvoCGarcía-PuigJA multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL studyClin Ther20022412613811833827
   PubMed Web of Science ®Google Scholar
• LacourcièreYA multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged ≥65 years with mild to moderate hypertensionClin Ther2000221213122411110232
   PubMed Web of Science ®Google Scholar
• ManciaGKorliparaKvan RossumPVillaGSilvertBAn ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartanBlood Press Monit2002713514212048432
   PubMed Web of Science ®Google Scholar
• NeutelJMGerminoFWSmithDComparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertensionJ Renin Angiotensin Aldosterone Syst20056848916470487
   PubMed Web of Science ®Google Scholar
• OparilSGuthrieRLewinAJAn elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartanClin Ther1998203984099663357
   PubMed Web of Science ®Google Scholar
• RosenstockJRossiLLinCSMacNeilDOsbakkenMThe effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide aloneJ Clin Pharm Ther19982343344010048504
   PubMed Web of Science ®Google Scholar
• HowePPhillipsPSainiRKassler-TaubKThe antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study GroupClin Exp Hypertens1999211373139610574419
   PubMed Web of Science ®Google Scholar
• RaskinPGuthrieRFlackJReevesRSainiRThe long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazideJ Hum Hypertens19991368368710516738
   PubMed Web of Science ®Google Scholar
• BobrieGI-ADD Study InvestigatorsI-ADD: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation studyClin Ther20123417201734 e322853847
   PubMed Web of Science ®Google Scholar
• BobrieGI-COMBINE Study InvestigatorsI-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation studyClin Ther2012341705171922853848
   PubMed Web of Science ®Google Scholar
• BobrieGDeloncaJMoulinCGiacominoAPostel-VinayNAsmarRA home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinationsAm J Hypertens2005181482148816280286
   PubMed Web of Science ®Google Scholar
• NeutelJMSmithDAmbulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertensionJ Int Med Res20053362063116372579
   PubMed Web of Science ®Google Scholar
• HwangY-SLuY-HIrbesartan monotherapy in systemic hypertension: an open-label, uncontrolled trialCurr Ther Res200263176185
   Web of Science ®Google Scholar
• KawanoYSatoYYoshinagaKA randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertensionHypertens Res2008311753176318971554
   PubMed Web of Science ®Google Scholar
• CoronelFCigarránSGarcía-MenaMHerreroJACalvoNPérez-FloresIIrbesartan in hypertensive non-diabetic advanced chronic disease. Comparative study with ACEINefrologia200828566018336132
   PubMed Web of Science ®Google Scholar
• OparilSWilliamsDChrysantSGMarburyTCNeutelJComparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertensionJ Clin Hypertens (Greenwich)2001328331811588406
   PubMedGoogle Scholar
• CushmanWCNeutelJMSaundersEEfficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapyAm J Geriatr Cardiol200817273618174757
   PubMedGoogle Scholar
• Al BalushiKAHabibJQAl-ZakwaniIComparative efficacy of irbesartan/hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in OmanMed Princ Pract20132226526923235349
   PubMed Web of Science ®Google Scholar
• ChrysantSGNeutelJMFerdinandKCINCLUSIVE investigatorsIrbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trialJ Natl Med Assoc200910130030719397219
   PubMed Web of Science ®Google Scholar
• FogariRZoppiAMugelliniAEfficacy and safety of two treatment combinations of hypertension in very elderly patientsArch Gerontol Geriatr20094840140518457886
   PubMed Web of Science ®Google Scholar
• FranklinSLapuertaPCoxDDonovanMInitial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapyJ Clin Hypertens (Greenwich)20079152218046108
   PubMedGoogle Scholar
• FranklinSSNeutelJMEfficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factorsJ Clin Hypertens (Greenwich)20101248749420629810
   PubMed Web of Science ®Google Scholar
• HuangQFShengCSLiYMaGSDaiQYWangJGINCENT InvestigatorsEfficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertensionDrugs R D20131310911723605903
   PubMedGoogle Scholar
• KocharMGuthrieRTriscariJKassler-TaubKReevesRAMatrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertensionAm J Hypertens19991279780510480473
   PubMed Web of Science ®Google Scholar
• Meaney-MendioleaEMorales-VillegasEnriqueVélez-Tello de MenesesMarioClinical effectiveness of irbesartan and irbesartan plus hydrochlorothiazide in women with mild to moderate essential hypertensionClin Drug Investig200019431439
   Web of Science ®Google Scholar
• NeutelJMFranklinSSOparilSBhaumikAPtaszynskaALapuertaPEfficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertensionJ Clin Hypertens (Greenwich)2006885085917170610
   PubMedGoogle Scholar
• OfiliEOCableGNeutelJMSaundersEEfficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the INCLUSIVE trialJ Womens Health (Larchmt)20081793193818681815
   PubMed Web of Science ®Google Scholar
• NeutelJMSaundersEBakrisGLThe efficacy and safety of low- and high- dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trialJ Clin Hypertens (Greenwich)2005757858616227760
   PubMedGoogle Scholar
• NeutelJMFranklinSSLapuertaPBhaumikAPtaszynskaAA comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertensionJ Hum Hypertens20082226627417928878
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesACC Current Journal Review20021126
   Google Scholar
• ParvingHHLehnertHBröchner-MortensenJGomisRAndersenSArnerPIrbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study GroupThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med200134587087811565519
   PubMed Web of Science ®Google Scholar
• de AlvaroFVelascoOHonoratoJCalvoCParrondoIKORAL HT InvestigatorsMicroalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartanKidney Int Suppl200593S29S3415613064
   PubMedGoogle Scholar
• LehnertHBramlagePPittrowDKirchWRegression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment: an observational study in 38,016 patients in primary careClin Drug Investig200424217225
   PubMed Web of Science ®Google Scholar
• SassoFCCarbonaraOPersicoMIrbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover studyDiabetes Care2002251909191312401731
   PubMed Web of Science ®Google Scholar
• GaudioCFerriFMGiovanniniMComparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophyJ Cardiovasc Pharmacol20034262262814576510
   PubMed Web of Science ®Google Scholar
• MalmqvistKKahanTEdnerMBergfeldtLComparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA)Am J Cardiol2002901107111212423712
   PubMed Web of Science ®Google Scholar
• MalmqvistKKahanTEdnerMRegression of left ventricular hypertrophy in human hypertension with irbesartanJ Hypertens2001191167117611403367
   PubMed Web of Science ®Google Scholar
• Müller-BrunotteREdnerMMalmqvistKKahanTIrbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophyJ Hypertens20052363364015716707
   PubMed Web of Science ®Google Scholar
• AnnemansLDemarteauNHuSAn Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathyValue Health20081135436417888064
   PubMed Web of Science ®Google Scholar
• CoyleDRodbyRSorokaSCost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspectiveClin Ther2007291508152317825702
   PubMed Web of Science ®Google Scholar
• CoyleDRodbyRAEconomic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in CanadaCan J Cardiol200420717914968145
   PubMed Web of Science ®Google Scholar
• EkmanMBienfait-BeuzonCJacksonJCost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for SwedenJ Hum Hypertens20082284585518633426
   PubMed Web of Science ®Google Scholar
• ManiadakisNEkmanMFragoulakisVPapagiannopoulouVYfantopoulosJEconomic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in GreeceEur J Health Econ20111225326120411401
   PubMed Web of Science ®Google Scholar
• PalmerAJAnnemansLRozeSCost-effectiveness of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: the Italian perspectivePharmacoeconomics200514357
   Google Scholar
• PalmerAJAnnemansLRozeSCost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal diseaseDiabetes Care2004271897190315277414
   PubMed Web of Science ®Google Scholar
• PalmerAJAnnemansLRozeSIrbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuriaKidney Int Suppl200567S52S5415613069
   PubMedGoogle Scholar
• RodbyRAChiouCFBorensteinJThe cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathyClin Ther2003252102211912946554
   PubMed Web of Science ®Google Scholar
• PalmerAJAnnemansLRozeSLamotteMRodbyRABilousRWAn economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK settingJ Hum Hypertens20041873373815116142
   PubMed Web of Science ®Google Scholar
• PalmerAJAnnemansLRozeSLamotteMRodbyRACordonnierDJAn economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settingsNephrol Dial Transplant2003182059206613679481
   PubMed Web of Science ®Google Scholar
• PalmerAJRozeSValentineWJHealth economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in SwitzerlandSwiss Med Wkly200613634635216779715
   PubMed Web of Science ®Google Scholar
• PalmerAJValentineWJRayJAIrbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysisInt J Clin Pract2007611626163317877649
   PubMed Web of Science ®Google Scholar
• PalmerAJValentineWJRayJARozeSMuszbekNHealth economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysisEur J Health Econ2007816116817237927
   PubMed Web of Science ®Google Scholar
• PalmerAJValentineWJTuckerDMA French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertensionCurr Med Res Opin2006222095210017076969
   PubMed Web of Science ®Google Scholar